Molnupiravir is currently being developed by Merck & Co. Inc. in collaboration with Ridgeback Biotherapeutics, which licensed the drug from DRIVE (founded by Emory chemist Dennis Liotta) in 2020. It could be the first oral antiviral medicine to treat COVID-19. Continue readingMolnupiravir and Drug Development at Emory
DRIVE seeks disease-fighting solutions via a different paradigm than big pharmaceutical industry. The New York Times features an opinion piece titled “In the Race for a Covid-19 Pill, a Little Lab Plays a Big Role.”Continue readingLiotta Group and DRIVE featured in New York Times
Dr. Douglas Mulford is featured in a recent Emory Report article about innovative approaches to online teaching. He discusses the logistical challenge of moving lab courses online, including new methods for promoting teamwork between students. Additionally, he discusses creating dynamic online lectures to keep students engaged. “Too much of what we think of as online…Continue readingChemistry featured in Emory Report for innovative online teaching
The Department of Chemistry has launched a new website to provide information regarding our response to COVID-19. The department is following ALL university-level guidance surrounding COVID-19. The website provides chemistry-specific details related to these university-level policies. The website also includes a form where you can submit anonymous questions, concerns, or suggestions to chemistry leadership. Anonymous…Continue readingChemistry launches COVID-19 website
